Your browser doesn't support javascript.
COVID-19 Vaccination for Persons with Parkinson's Disease: Light at the End of the Tunnel?
Bloem, Bastiaan R; Trenkwalder, Claudia; Sanchez-Ferro, Alvaro; Kalia, Lorraine V; Alcalay, Roy; Chiang, Han-Lin; Kang, Un Jung; Goetz, Christopher; Brundin, Patrik; Papa, Stella M.
  • Bloem BR; Radboud University Nijmegen Medical Center, Donders Institute for Brain, Cognition and Behavior, Department of Neurology, Nijmegen, the Netherlands.
  • Trenkwalder C; Paracelsus-Elena Klinik, Kassel, Department of Neurosurgery, University Medical Center, Goettingen, Germany.
  • Sanchez-Ferro A; HM CINAC, Hospital Universitario HM Puerta del Sur and 12 de Octubre Hospital, Madrid, Spain.
  • Kalia LV; Morton and Gloria Shulman Movement Disorders Clinic and the Edmond J Safra Program in Parkinson's Disease, Toronto Western Hospital, Division of Neurology, Department of Medicine, University of Toronto, Toronto, ON, Canada.
  • Alcalay R; Department of Neurology, Columbia University Irving Medical Center, New York, NY, USA.
  • Chiang HL; Neurological Institute, Taipei Veterans General Hospital, Taipei, Taiwan.
  • Kang UJ; Department of Neurology, New York University Grossman School of Medicine, New York, NY, USA.
  • Goetz C; Department of Neurology, Rush University Medical Center, Rush University Medical School, Chicago, IL, USA.
  • Brundin P; Parkinson's Disease Center, Department for Neurodegenerative Science, Van Andel Institute, Grand Rapids, MI, USA.
  • Papa SM; Yerkes National Primate Research Center, Department of Neurology, Emory University School of Medicine, Atlanta, GA, USA.
J Parkinsons Dis ; 11(1): 3-8, 2021.
Article in English | MEDLINE | ID: covidwho-1058393
ABSTRACT
Several COVID-19 vaccines have recently been approved for emergency use according to governmental immunization programs. The arrival of these vaccines has created hope for people with Parkinson's disease (PD), as this can help to mitigate their risk of becoming infected with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which can lead to serious, life-threatening disease, at least among those with more advanced PD. However, both persons with PD and physicians looking after these individuals have expressed concerns about the vaccine's efficacy and safety in the specific context of PD and its symptomatic treatment. Here, we discuss our perspective on these concerns, based on our interpretation of the literature plus the unfolding experience with widespread vaccination in the population at large. Because the benefits and risks of COVID-19 vaccines do not appear to be different than in the general population, we recommend COVID-19 vaccination with approved vaccines to persons with PD, unless there is a specific contraindication. Some caution seems warranted in very frail and terminally ill elderly persons with PD living in long-term care facilities.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: Parkinson Disease / COVID-19 Vaccines / COVID-19 Type of study: Prognostic study Topics: Long Covid / Vaccines Limits: Aged / Female / Humans / Male / Middle aged Language: English Journal: J Parkinsons Dis Year: 2021 Document Type: Article Affiliation country: JPD-212573

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Parkinson Disease / COVID-19 Vaccines / COVID-19 Type of study: Prognostic study Topics: Long Covid / Vaccines Limits: Aged / Female / Humans / Male / Middle aged Language: English Journal: J Parkinsons Dis Year: 2021 Document Type: Article Affiliation country: JPD-212573